Novel treatment mechanism for diabesity published in Molecular Metabolism

Scientists at Excellerate Bioscience contributed molecular pharmacology expertise to the pre-clinical evaluation of a new treatment for diabetes and obesity, published this month in Molecular Metabolism by Atrogi AB (Stockholm, Sweden).

The work identified beta-adrenoceptor agonist drugs with preferential signalling to glucose uptake and lipid metabolism pathways.

These effects in skeletal muscle and adipocytes improved glucose homeostasis, reduced body weight and fat content in models of diet induced obesity, providing a novel treatment paradigm. The collaboration between Atrogi AB, Excellerate and other academic and industry partners across Europe was supported by a 1 million euro EU Eurostars Award from 2021 – 2023.

PDF link to publication paper: LINK

Please contact us to find out how Excellerate’s advanced expertise in receptor pharmacology can support pre-clinical mechanism of action and lead optimisation studies.